- A look ahead at 2016 and beyond...
- New generation of IT tools - what changes?
- How to prepare for the new IT tools - perspectives of two big companies
- REACH 2018: How to get organised with your co-registrants
- Want to know about… how a substance is selected for regulatory risk management?
- Alternatives to animal testing – what's new in 2016?
- Want to know about...the Review Programme?
- Biocides - state of play and challenges ahead
- Supply chain communication - help yourself, use the tools
- Guest column: Innovation, transparency and collaboration
- Sustainable development for a safer world
Send your feedback to:echanewsletter (at) echa.europa.eu
Article related to: REACH
Want to know about… how a substance is selected for regulatory risk management?
Ever wondered how your substance is selected for risk management? We have chosen two substances as examples to show you how it works.
From risk management option analysis to the Candidate List
What you can do
Harmonised classification and labelling (CLH)
The aim of the CLH screening is to identify substances on the EU market that are not currently harmonised, but for which a harmonised classification and labelling is justified. Priority is given to substances with potential carcinogenic, mutagenic and toxic for reproduction (CMR) properties, or respiratory sensitising properties and with wide dispersive uses.
ECHA has developed scenarios that analyse the self-classifications from registrants and notifiers of substances with CMR and respiratory sensitisation properties. In addition, substances that are structurally similar to these are identified, as are substances with these properties that have been identified by external bodies (e.g. non-EU authorities).
Substance of very high concern (SVHC)
The SVHC screenings focus on substances with harmonised classifications such as CMR category 1A/1B, and with PBT or endocrine disrupting properties at the level of the substance, its constituents or degradation products. Furthermore, the wide-dispersiveness of the uses is considered.
Text by Nedyu Yasenov
| || |
Sign in to comment and/or rate this article.
Committee for Risk Assessment:
Committee for Socio-Economic
Biocidal Products Committee:
Member State Committee:
4-8 February (tentative)
Management Board meeting: